Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2022 | Polycythemia vera: disease outcomes, unmet needs and therapeutic strategies

Jerry Spivak • 10 Nov 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Ruxolitinib

Jerry Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD, gives a presentation on disease outcomes, unmet needs and therapeutic strategies in polycythemia vera (PV) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Jerry Spivak

Polycythemia vera: myths, mechanisms, and management
Polycythemia vera: myths, mechanisms, and management
Jerry Spivak • 24 Nov 2022
Challenges in the treatment and management of ET and the need to improve therapeutic approaches
5:21
Challenges in the treatment and management of ET and the need to improve therapeutic approaches
Jerry Spivak • 26 Aug 2022
The need to improve diagnostic criteria in PV and other challenges in the field
6:04
The need to improve diagnostic criteria in PV and other challenges in the field
Jerry Spivak • 26 Aug 2022
The importance of patient perspectives during treatment journeys
2:04
The importance of patient perspectives during treatment journeys
Jerry Spivak • 26 Aug 2022

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Jerry Spivak • 7 Dec 2025
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Jerry Spivak • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Jerry Spivak • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Jerry Spivak • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals